Abstract
Vaccines have saved more lives than any other medical intervention
throughout human history by preventing the spread of infectious
diseases. However, despite several decades of research, there is no
effective vaccine against fast evolving viruses such as the human
immunodeficiency virus (HIV) and the hepatitis C virus (HCV). A
confounding factor in the development of a HIV or HCV vaccine is that
these viruses have a unique ability to make a lot of mutations in their
genetic code. This enables them to escape the human immune system while
retaining their ability to propagate infection. For developing a vaccine
against such viruses, scientists are developing novel strategies which
seek to target specific parts of the virus that are most vulnerable
(i.e., where it is difficult for the virus to survive mutations) in
order to induce a focused and potentially effective immune response. To
determine the existence and location of such parts of HIV and HCV,
initial studies have leveraged recently-available sequence data for
these viruses, and looked for those positions in the genome for which
the frequency of mutation was lowest. Unfortunately, vaccines based on
such first-order statistics have not enjoyed much success, and there is
increasing evidence suggesting that interactions between mutations is
also important and must be considered when designing an effective
vaccine against HIV and HCV. It is almost impossible to determine
effects of interactions between all mutations experimentally as it
requires performing billions of experiments. In this article, we explain
how by leveraging virus sequence data, mutational interactions can be
estimated using statistical techniques and incorporated in designing
novel and potentially effective vaccine strategies against such
fast-evolving viruses.